PAVmed Inc (NASDAQ: PAVM) closed the day trading at $2.14 down -21.61% from the previous closing price of $2.73. In other words, the price has decreased by -$0.5550 from its previous closing price. On the day, 192759 shares were traded.
Ratios:
For a better understanding of PAVM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.43 and its Current Ratio is at 0.45.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on March 30, 2021, initiated with a Overweight rating and assigned the stock a target price of $8.
On November 05, 2020, Ascendiant Capital Markets started tracking the stock assigning a Buy rating and target price of $5.
On June 28, 2018, Maxim Group started tracking the stock assigning a Buy rating and target price of $5.Maxim Group initiated its Buy rating on June 28, 2018, with a $5 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PAVM now has a Market Capitalization of 21.98M and an Enterprise Value of 48.39M. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.01. Its current Enterprise Value per Revenue stands at 31.94 whereas that against EBITDA is -0.59.
Stock Price History:
Over the past 52 weeks, PAVM has reached a high of $8.07, while it has fallen to a 52-week low of $1.60. The 50-Day Moving Average of the stock is 2.2791, while the 200-Day Moving Average is calculated to be 4.0424.
Shares Statistics:
Over the past 3-months, PAVM traded about 74.95K shares per day on average, while over the past 10 days, PAVM traded about 70.9k shares per day. A total of 8.58M shares are outstanding, with a floating share count of 7.59M. Insiders hold about 17.25% of the company’s shares, while institutions hold 12.39% stake in the company. Shares short for PAVM as of Mar 15, 2024 were 368.67k with a Short Ratio of 4.92, compared to 396.51k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.58% and a Short% of Float of 4.86%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$1.67 for the current quarter, with a high estimate of -$1.48 and a low estimate of -$1.82, while EPS last year was -$2.85. The consensus estimate for the next quarter is -$1.58, with high estimates of -$1.45 and low estimates of -$1.67.
Analysts are recommending an EPS of between -$5.69 and -$6.63 for the fiscal current year, implying an average EPS of -$6.01. EPS for the following year is -$3.44, with 2 analysts recommending between -$2.05 and -$4.83.
Revenue Estimates
4 analysts predict $1.09M in revenue for the current quarter. It ranges from a high estimate of $1.1M to a low estimate of $1.08M. As of the current estimate, PAVmed Inc’s year-ago sales were $446k, an estimated increase of 144.40% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $1.35M, an increase of 713.30% over than the figure of $144.40% in the same quarter last year. There is a high estimate of $1.5M for the next quarter, whereas the lowest estimate is $1.2M.
A total of 4 analysts have provided revenue estimates for PAVM’s current fiscal year. The highest revenue estimate was $9.4M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $6.88M. In the same quarter a year ago, actual revenue was $2.45M, up 180.60% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $17.61M in the next fiscal year. The high estimate is $37.8M and the low estimate is $7.5M. The average revenue growth estimate for next year is up 156.00% from the average revenue estimate for this year.
